CEO Sean Duffy Sells Over $4.2M in Omada Health Stock
OMDA is trading near its 52-week low of $14.14 (9.3% above the low).
Summary
Omada Health's CEO, Sean P. Duffy, sold over $4.2 million worth of common stock following the exercise of options, representing a notable reduction in his direct holdings.
Key Events · Ownership and Investor Activity · OMDA
-
CEO Sells Significant Stake
Sean P. Duffy, CEO and Director, sold common stock valued at approximately $4.25 million in open market transactions on January 12-13, 2026.
-
Option Exercise Preceded Sale
The sales followed the exercise of options to acquire 271,275 shares at a price of $2.55 per share, which were then sold in the open market between $15.35 and $15.99.
-
Reduction in Direct Holdings
Post-transaction, the CEO's direct holdings decreased to 357,123 shares.
Analysis · OMDA · Industrial Applications And Services
The Chief Executive Officer of Omada Health, Sean P. Duffy, executed a significant sale of company stock totaling over $4.2 million. This transaction involved exercising options at a low strike price and immediately selling the acquired shares in the open market. While the options were set to expire imminently, a sale of this magnitude by a key executive can be interpreted as a move to diversify personal holdings or a signal of reduced confidence. Investors should monitor future insider activity and company performance closely.
How filings like this one have moved
In the 30 days to Sep 13, 2026, 42% of the 419 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.47%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, OMDA was trading at $15.45 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $897.6M. The 52-week trading range was $14.14 to $28.40. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.